Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation
Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…Dopamine Agonists and Postural Disorders in Parkinson’s disease
Objective: To evaluate the relationship between treatment with DA and the development of postural disorders (CC, PS and AC) in patients with PD. Background: Stood…Tacrolimus induced parkinsonism presenting as freezing of gait and speech
Objective: Tacrolimus a calcineurin inhibitor is the most widely used immunosuppressant in post transplant patients. Mild adverse effects like tremors and parasthesia and occasionally major…Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.
Objective: We set out to compare movement patterns induced by systemic administration of l-dopa versus D1- or D2-class DA receptor agonists in mice with unilateral…Pharmacological modulation of mGluR5 improves dyskinesias mediated by D1 but not D2 receptor stimulation.
Objective: To determine whether pharmacological inhibition of metabotropic glutamate receptor type 5 (mGluR5) can improve dyskinesias mediated by D1- or D2-type dopamine (DA) receptors (D1R…Adding cues to a rat gambling task potentiates the increase in premature responding in response to chronic D2/3 agonist ropinirole without mitigating preference for risk
Objective: Investigating the effect of chronic administration of the dopamine D2/3 agonist ropinirole on a cued model of gambling behaviour in rats. Background: Dopamine D2/3 agonists…Osmotic demyelination syndrome with dystonia and parkinsonism responsive to dopaminergic therapy
Objective: To present a case of delayed-onset dystonia and parkinsonism secondary to osmotic demyelination syndrome, with dramatic response to pramipexole 3mg per day. Background: Osmotic…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…Priapism and hypersexuality associated with rotigotine in an elderly Parkinsonian patient: A case report
Objective: To describe reversible rotigotine - induced priapism and hypersexuality in a 79-year-old left-handed male with Parkinson's disease (PD). Background: Priapism is a urological emergency…Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center
Objective: To describe the frequency, characteristics and potential risk factors for Dopamine Agonist Withdrawal Syndrome (DAWS). Background: Dopamine agonists are a mainstay of treatment for…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »